Project Grant R01DA057931

Award Date 6/1/24
Completion Date 3/31/29
Dollars Obligated $2M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Huntington, WV 25755, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) has awarded a $492,000 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the University of Chicago to conduct a multidimensional study on the genetic and epigenetic factors underlying cocaine addiction. The 5-year project aims to: Perform high-resolution chromatin accessibility and DNA methylation profiling to delineate cell-type and circuit-specific epigenetic changes following cocaine self-administration in mice. This will...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support a $346,911 cross-species research study to identify early life environmental and genetic risk factors for substance use disorders (SUDs). The key objectives are to: 1) determine how early life environment influences neurocognitive development and its relationship to adult impulsivity behaviors; 2) identify genomic networks associated...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a multivariate genome-wide association analysis of opioid-related traits in a diverse population of over 500,000 individuals. The $715,238 award, effective January 15, 2025 through November 30, 2029, will enable researchers at the University of California, San Diego to investigate the genetic basis of pre-addiction opioid use stages,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to explore the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders. The $314,225 award, effective July 31, 2024 through February 28, 2025, will fund a study conducted by the University of Washington to: 1) Define the behavioral profile of dual opioid-methamphetamine use disorders in a...
This federal Cooperative Agreement award of $2,094,403.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify genes that affect behaviors associated with substance use disorders (SUDs). The University of California, Los Angeles (UCLA) will conduct a novel mechanism-to-gene strategy to genetically map circuit-driven behavioral outputs related to anxiety and SUDs. The key research activities...
This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research aimed at understanding and disrupting fentanyl-linked context memories to prevent addiction relapse. The $153,512 award to the Children's Hospital of Philadelphia (CHOP) will fund experiments to determine if inhibiting or stimulating dentate gyrus neurons during reward-context memory encoding can manipulate drug-linked context...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $944,888 to the Seattle Children's Research Institute to conduct a deep analysis of the transcriptome in rats to understand the genetics of substance use disorders. The 5-year project, starting July 1, 2025, will produce an unprecedented atlas of variation in the rat transcriptome as a mediator of substance use disorder-relevant...
This Project Grant award of $1,447,919.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on cocaine addiction and the "need-state hypothesis" at Pennsylvania State University's Milton S. Hershey Medical Center. The research aims to use an animal model to identify individual vulnerability to cocaine addiction early in the disease state, and explore the use of a known satiety agent, glucagon-like...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,039,420 to The Medical University of South Carolina (MUSC) to conduct research on the neurobiological mechanisms underlying the facilitation and disinhibition of opioid and alcohol seeking behaviors. The key goals of this 5-year project are to: 1) characterize the transcriptomic profiles and functional roles of unique neuronal...
This Project Grant award of $1,159,396 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research at Vanderbilt University to investigate the molecular and epigenetic mechanisms underlying cocaine addiction. The research aims to understand how cocaine triggers the recruitment and maintenance of specific neuronal ensembles in the nucleus accumbens (NAc) that drive addictive behaviors. Key focus areas include examining...

DISSECTING THE SHARED GENETIC MECHANISMS DRIVING FENTANYL ADDICTION, COCAINE ADDICTION, AND INCENTIVE SENSITIZATION USING THE COLLABORATIVE CROSS MOUSE PANEL - PROJECT ABSTRACT FENTANYL ADDICTION IS A HIGHLY HERITABLE DISEASE AND A CRITICAL PUBLIC HEALTH CRISIS. IN 2022, FENTANYL OVERDOSE WAS THE LEADING CAUSE OF DEATH FOR US ADULTS AGED 18 - 45. THIS STRIKING STATISTIC UNDERSCORES THE URGENT NEED TO DISCOVER AND CHARACTERIZE THE GENETIC DRIVERS OF FENTANYL ADDICTION. IN THIS REGARD, DRUG-INDUCED INCENTIVE SENSITIZATION IN BRAIN REWARD SYSTEMS IS A FUNDAMENTAL ADDICTION VECTOR. THIS HYPOTHESIS (THE INCENTIVE SENSITIZATION THEORY OF ADDICTION) POSITS THAT, OVER TIME, BRAIN REWARD SYSTEMS BECOME HYPERSENSITIZED TO THE ENVIRONMENTAL STIMULI THAT ACCOMPANY DRUG USE. THE CONSEQUENCE IS PATHOLOGICAL INCENTIVE MOTIVATION (I.E., "WANTING") FOR THE DRUG UPON EXPOSURE TO THE DRUG-PAIRED STIMULI. ALTHOUGH FENTANYL ADDICTION AND INCENTIVE SENSITIZATION ARE HIGHLY HERITABLE IN HUMANS AND MICE, THE GENETIC ROLE OF INCENTIVE SENSITIZATION IN FENTANYL ADDICTION IS UNKNOWN. THE OVERARCHING GOAL OF THIS PROJECT IS TO IDENTIFY THE GENETIC MECHANISMS THROUGH WHICH INCENTIVE SENSITIZATION DRIVES ADDICTION-LIKE FENTANYL TAKING AND SEEKING. THIS GOAL WILL BE ACCOMPLISHED THROUGH THE INTEGRATION OF ADVANCED MOUSE RESOURCES, GOLD STANDARD BEHAVIOR AND NEUROPHYSIOLOGY ASSAYS, AND CUTTING-EDGE TRANSCRIPTOMICS. THE COLLABORATIVE CROSS (CC) RECOMBINANT INBRED MOUSE PANEL, WHICH CONTAINS 90% OF MOUSE ALLELES, WILL BE USED TO MAXIMIZE GENETIC AND PHENOTYPIC DIVERSITY. IN AIM 1, WE WILL USE INTRAVENOUS FENTANYL SELF-ADMINISTRATION TO IDENTIFY GENETIC MECHANISMS UNDERLYING CLASSICAL PHARMACOLOGICAL PHENOTYPES AND ADDICTION-LIKE BEHAVIORS IN MALE AND FEMALE MICE FROM 40 CC STRAINS. IN AIM 2, WE WILL USE PAVLOVIAN CONDITIONED APPROACH AND RNA-SEQ TO IDENTIFY GENETIC AND NUCLEUS ACCUMBENS TRANSCRIPTOMIC MECHANISMS UNDERLYING INCENTIVE SENSITIZATION IN MALE AND FEMALE MICE FROM 40 CC STRAINS. IN AIM 3, WE WILL USE SNRNA-SEQ, ISO-SEQ, ELECTROPHYSIOLOGY, AND VOLTAMMETRY TO IDENTIFY CELL-TYPE AND ISOFORM SPECIFIC ADDICTION MECHANISMS IN TWO CC STRAINS EXHIBITING EXTREME NUCLEUS ACCUMBENS-DRIVEN VULNERABILITY AND RESISTANCE, RESPECTIVELY, TO BOTH IV FENTANYL AND IV COCAINE SELF-ADMINISTRATION. USING DATA FROM THESE THREE AIMS, A COMPREHENSIVE SYSTEMS GENETICS ANALYSIS INCLUDING QTL MAPPING, EQTL MAPPING, GENETIC CORRELATION, AND DIFFERENTIAL EXPRESSION WILL BE PERFORMED TO IDENTIFY CELL-TYPE SPECIFIC AND ISOFORM SPECIFIC TRANSCRIPTOMIC SIGNATURES IN NUCLEUS ACCUMBENS THAT PREDICT BOTH PATHOLOGICAL INCENTIVE MOTIVATION AND ADDICTION-LIKE FENTANYL SELF-ADMINISTRATION. SUCCESSFUL COMPLETION OF THESE AIMS WILL PROVIDE A FOUNDATION FOR FUTURE DEEP CHARACTERIZATION OF IDENTIFIED MECHANISMS AND A LASTING COMMUNITY RESOURCE ENABLING GENETIC CORRELATIONAL ANALYSIS AMONG THE CC PANEL ACROSS PHENOTYPES, EXPERIMENTS, AND LABORATORIES. ULTIMATELY, THIS WORK WILL CONTRIBUTE TO THE DEVELOPMENT OF NOVEL, MORE EFFECTIVE ADDICTION TREATMENTS.

Posted 5/27/24, 12:00 AM